SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------------
AMENDMENT NO. 1 TO
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
JUNE 2, 1999
(Date of Report - earliest event reported)
TRIANGLE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
DELAWARE 000-21589 56-1930728
(State of incorporation or organization) (Commission (IRS Employer
File Number) Identification No.)
4 University Place, 4611 University Drive, Durham, North Carolina 27707
Registrant's telephone number, including area code: (919)493-5980
NONE
-----------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 7. EXHIBITS.
* 2.1 Collaboration Agreement, dated as of June 2, 1999 by and
between Triangle Pharmaceuticals, Inc. and Abbott Laboratories.
* 2.2 Co-Promotion Agreement, dated as of June 2, 1999 by and between
Triangle Pharmaceuticals, Inc. and Abbott Laboratories.
+ 2.3 Triangle Pharmaceuticals, Inc. Common Stock Purchase Agreement,
dated as of June 2, 1999 by and between Triangle
Pharmaceuticals, Inc. and Abbott Laboratories.
+ 2.4 Triangle Pharmaceuticals, Inc. Stockholder Rights Agreement,
dated as of June 2, 1999 by and between Triangle
Pharmaceuticals, Inc. and Abbott Laboratories.
# 4.1 Amendment to Rights Agreement, dated as of June 2, 1999 by and
between Triangle Pharmaceuticals, Inc. and Abbott Laboratories.
+ 99.1 Press Release dated June 3, 1999.
* Certain confidential portions of this Exhibit were omitted by
means of marking such portions with an asterisk (the "Mark").
This Exhibit has been filed with the Secretary of the
Commission without the Mark pursuant to the Company's
application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
# Previously filed.
+ Filed as an exhibit to Abbott Laboratories' Schedule 13D filed
with the Securities and Exchange Commission on June 11, 1999
and incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
TRIANGLE PHARMACEUTICALS, INC.
Date: November 2, 1999 By: /s/ Thomas R. Staab, II
-------------------------------------
Thomas R. Staab, II
Acting Chief Financial Officer and Treasurer
TRIANGLE PHARMACEUTICALS, INC.
FORM 8-K
EXHIBIT INDEX
EXHIBIT DOCUMENT DESCRIPTION
NUMBER --------------------
-------
* 2.1 Collaboration Agreement, dated as of June 2, 1999 by and
between Triangle Pharmaceuticals, Inc. and Abbott
Laboratories.
* 2.2 Co-Promotion Agreement, dated as of June 2, 1999 by and
between Triangle Pharmaceuticals, Inc. and Abbott
Laboratories.
+ 2.3 Triangle Pharmaceuticals, Inc. Common Stock Purchase
Agreement, dated as of June 2, 1999 by and between Triangle
Pharmaceuticals, Inc. and Abbott Laboratories.
+ 2.4 Triangle Pharmaceuticals, Inc. Stockholder Rights Agreement,
dated as of June 2, 1999 by and between Triangle
Pharmaceuticals, Inc. and Abbott Laboratories.
# 4.1 Amendment to Rights Agreement, dated as of June 2, 1999 by
and between Triangle Pharmaceuticals, Inc. and Abbott
Laboratories.
+ 99.1 Press Release dated June 3, 1999.
* Certain confidential portions of this Exhibit were omitted by
means of marking such portions with an asterisk (the "Mark").
This Exhibit has been filed with the Secretary of the
Commission without the Mark pursuant to the Company's
application requesting confidential treatment under Rule 24b-2
under the Securities Exchange Act of 1934, as amended.
# Previously filed.
+ Filed as an exhibit to Abbott Laboratories' Schedule 13D filed
with the Securities and Exchange Commission on June 11, 1999
and incorporated herein by reference.